Back to results
US 12,527,843 B2Granted
Immune-cell targeted bispecific chimeric proteins and uses thereof
AssigneesVib Vzw, Universiteit Gent, Centre National De La Recherche Scientifique, Universite De Montpellier
InventorsJan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
Claims11
A pharmaceutical formulation comprising:
- (a) a chimeric protein comprising:
- (i) a first targeting moiety comprising an antibody which specifically binds to CD20;
- (ii) a second targeting moiety comprising X-C motif chemokine ligand 1 (XCL1) or X-C motif chemokine ligand 2 (XCL2);
- (iii) a modified human interferon alpha 2 comprising an amino acid sequence having at least 95% identity with SEQ ID NO:
- 4 and having one or more amino acid substitution mutations at positions 144-154, relative to SEQ ID NO:
- 4, or positions corresponding thereto, that confer a reduced affinity or activity for its receptor relative to the wild type human interferon alpha 2;
- and
- (b) a pharmaceutically acceptable carrier.
5 more elements
Dependencies are inferred from the claim text.